CARDIOLOGY

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs), which improve clinical outcomes in people with chronic kidney disease (CKD) and/or systolic heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with CKD. However, their effect on hyperkalemia has not been systematically evaluated. Results from six trials were included comprising 49,875 participants assessing four SGLT2 inhibitors. 1,754 participants developed serious hyperkalemia and an additional 1,119 investigator-reported hyperkalemia events were recorded.  SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk and/or CKD, without increasing the risk of hypokalemia.

SGLT2 Inhibitors and Hyperkalemia Risk Reduction in Patients with Type 2 Diabetes and CKD: Clinical Insights and Evidence

ONCOLOGY

Study identifies the β-catenin/BCL9 pathway as a promising new therapeutic target for bladder cancer.

β-Catenin/BCL9 Pathway Emerges as New Target in Bladder Cancer

Researchers have identified the β-catenin/BCL9(L) signaling axis as a potential new therapeutic target in bladder cancer. The study found that the proteins BCL9 and BCL9L promote tumor cell growth, migration, and invasion. A novel inhibitor, ZW4864, disrupted this pathway, suppressing cancer cell proliferation and reducing the growth of bladder cancer organoids in laboratory models. The findings offer promising insights into developing targeted therapies for a disease that continues to present major treatment challenges.

ORTHOPAEDICS

A 10-minute exercise program improved hip function and helped most FAIS patients avoid surgery.

10-Minute Exercise Program Helps FAIS Patients Avoid Hip Surgery

A new study suggests that a simple, pelvic tilt-focused home exercise program can significantly improve symptoms in people with femoroacetabular impingement syndrome (FAIS), a common cause of hip pain. After six months of following the 10-minute HipFit10 program, 78% of participants avoided surgery and reported meaningful improvements in hip function and pain. The findings indicate that targeted physical therapy may offer a safe and effective nonoperative treatment option for many patients with FAIS.

NEUROLOGY

Study highlights the challenges of diagnosing rare adult prostatic rhabdomyosarcoma and the need for early detection.

Rare Prostatic Rhabdomyosarcoma Often Misdiagnosed in Adults

Researchers are calling for greater awareness of adult prostatic rhabdomyosarcoma (PRMS), an extremely rare and aggressive cancer that is frequently misdiagnosed as benign prostate disease due to its nonspecific early symptoms. A case study highlights the importance of multimodal imaging, including ultrasound and MRI, along with pathological biopsy for accurate diagnosis and staging. Early recognition of this rare malignancy could help reduce diagnostic delays and improve patient outcomes.

PEDIATRICS

Study defines normal breathing synchrony ranges that may improve diagnosis of sleep apnea in children.

New Breathing Marker May Improve Childhood Sleep Apnea Diagnosis

Researchers have established a normal range for thoracoabdominal asynchrony (TAA), a measure of breathing coordination between the chest and abdomen during sleep, in healthy children. The study found that children with obstructive sleep apnea (OSA) spent significantly more time with elevated TAA than healthy peers. Elevated TAA was also linked to REM sleep, sleeping on the back, snoring, and obesity. The findings suggest that TAA measurements from standard sleep studies could become a valuable tool for improving the diagnosis and management of pediatric sleep disorders.

GYNAECOLOGY - IVF

IVF study on preventing ovarian hyperstimulation syndrome has been retracted over concerns about trial methodology.

IVF Study on OHSS Prevention Retracted Due to Methodological Concerns

A widely cited study investigating the use of cabergoline combined with coasting to prevent ovarian hyperstimulation syndrome (OHSS) during IVF and ICSI treatment has been retracted. The journal's editors and publisher raised concerns about the study's randomization process, concluding that the trial did not meet the standards required for a randomized clinical study. As a result, the data and conclusions were deemed unreliable, underscoring the importance of rigorous research methods in reproductive medicine.

GASTROENTEROLOGY

New ICD-10 code K76.82 has significantly changed documentation and tracking of hepatic encephalopathy.

New ICD-10 Code Transforms Hepatic Encephalopathy Documentation

A new study shows that the introduction of ICD-10 code K76.82, specifically for hepatic encephalopathy (HE), has dramatically changed how the condition is documented in hospitalized patients with cirrhosis. Since its launch in October 2022, use of older, non-specific codes has sharply declined, while overall documentation of HE has increased. Researchers say future studies tracking HE trends, outcomes, and healthcare utilization must account for this major shift in coding practices.

DENTISTRY

Study finds jaw bone sequestra in MRONJ typically develop within 6–7 months after dental procedures.

Study Reveals Timing of Jaw Bone Damage in MRONJ Patients

A new study has shed light on the timing of sequestrum formation—a hallmark of medication-related osteonecrosis of the jaw (MRONJ)—in patients managed conservatively after dental procedures. Researchers found that dead bone fragments typically developed and were detected about six to seven months after treatment. Continuing medication after invasive dental procedures was linked to delayed sequestrum formation, while patients with osteoporosis developed sequestra earlier than those with cancer. The findings could help clinicians optimize monitoring and treatment strategies for MRONJ patients.

ENDO-DIABETOLOGY

Study finds higher TMAO levels do not impair insulin sensitivity or increase type 2 diabetes risk.

Study Questions TMAO's Role in Causing Type 2 Diabetes

A new clinical study suggests that trimethylamine N-oxide (TMAO), a compound produced by gut microbes from dietary nutrients such as choline, may not directly cause insulin resistance or type 2 diabetes. Researchers significantly increased TMAO levels in healthy adults through short-term and four-week supplementation but found no changes in insulin sensitivity, glucose tolerance, or blood sugar control. The findings challenge the idea that elevated TMAO itself is a causal driver of diabetes and suggest the relationship may be more complex.

New guidance highlights personalized strategies to improve heart failure care and outcomes in older adults.

Experts Urge Personalized Heart Failure Care for Older Adults

As heart failure cases continue to rise, experts are calling for more personalized care for older adults, who face unique challenges in accessing and managing guideline-recommended therapies. A new scientific statement highlights strategies to optimize treatment by addressing common issues such as multiple chronic conditions, polypharmacy, frailty, and social barriers. The authors emphasize shared decision-making and tailored care plans to improve outcomes and reduce the burden of heart failure in people aged 65 years and older.

Study finds cervical lymph node metastases predict poorer response to pembrolizumab in oral cancer patients.

Lymph Node Metastases Linked to Poorer Immunotherapy Outcomes in Oral Cancer

A new study suggests that recurrent or metastatic oral cavity squamous cell carcinoma (OCSCC) patients with cervical lymph node metastases may derive less benefit from pembrolizumab immunotherapy. Researchers found that the presence of metastatic neck lymph nodes at treatment initiation was independently associated with significantly poorer six-month progression-free survival. The findings indicate that regional disease burden could serve as an important prognostic marker and help guide treatment decisions for patients receiving immune checkpoint inhibitors.

OPHTHALMOLOGY

Study shows Clareon PanOptix Toric lens delivers excellent vision and stable performance after cataract surgery.

Clareon PanOptix Toric Lens Shows Strong Visual Outcomes in Real-World Study

A real-world study found that the Clareon PanOptix Toric multifocal intraocular lens (IOL) provided excellent distance, intermediate, and near vision after cataract surgery while maintaining strong rotational stability. At 12 weeks, 85% of implanted eyes showed minimal lens rotation of 5 degrees or less, and patients reported significant improvements in quality of vision and satisfaction. Researchers say the lens demonstrated reliable performance in routine clinical practice, though larger studies are needed to further validate its stability.

DERMATOLOGY

Study finds prediction models may help identify psoriasis patients at risk of developing psoriatic arthritis.

Prediction Models Could Help Identify Psoriasis Patients at Risk of Psoriatic Arthritis

A new review highlights the growing potential of prediction models to identify psoriasis patients at higher risk of developing psoriatic arthritis (PsA). Researchers analyzed 490 prediction models that incorporated factors such as age, genetics, body weight, disease severity, and lifestyle characteristics. While some models showed strong predictive ability, few underwent external validation, raising concerns about their real-world reliability. Experts say better-designed and validated tools could help dermatologists identify high-risk patients earlier and potentially prevent disease progression.

Large study finds surgeon-patient sex matching does not affect complication rates after cataract surgery.

Surgeon-Patient Sex Match Does Not Impact Cataract Surgery Outcomes

A large 16-year study involving more than 30,000 cataract surgeries found that matching a patient's sex with that of their surgeon does not influence the risk of surgical complications. Researchers observed similar complication rates in both sex-concordant and sex-discordant surgeon-patient pairs, with complications occurring in only 3.5% of cases. The findings suggest that cataract surgery outcomes are comparable regardless of surgeon-patient sex and reinforce the importance of focusing on clinical expertise and quality of care rather than demographic characteristics.

RHEUMATOLOGY

Research identifies TLR7 as a promising therapeutic target that could reshape future treatment for lupus patients.

TLR7 Emerges as a Promising New Target for Lupus Treatment

New research highlights Toll-like receptor 7 (TLR7) as a key driver of systemic lupus erythematosus (SLE) and a promising target for future therapies. Genetic studies show that abnormal TLR7 signaling can trigger lupus by promoting autoantibody production and excessive immune activation. Early clinical trials of oral TLR7-TLR8 antagonists have demonstrated durable suppression of inflammatory pathways and shown clinical benefits in SLE and cutaneous lupus. These findings could pave the way for more accessible, targeted treatments for a disease with significant unmet medical needs.

New screening tool helps identify medically complex children who need coordinated medical home care services.

New Tool Identifies Children Needing Medical Home Care Referrals

Researchers have developed and validated the Pediatric Medical Home Screening Tool (PMHST), a new instrument designed to help hospital teams identify children with medical complexity who would benefit from early referral to a medical home care model before discharge. The tool demonstrated 82% agreement in classifying medically complex infants and young children and could improve care transitions, coordination, patient safety, and overall quality of care.

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs), which improve clinical outcomes in people with chronic kidney disease (CKD) and/or systolic heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with CKD. However, their effect on hyperkalemia has not been systematically evaluated. Results from six trials were included comprising 49,875 participants assessing four SGLT2 inhibitors. 1,754 participants developed serious hyperkalemia and an additional 1,119 investigator-reported hyperkalemia events were recorded. SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk and/or CKD, without increasing the risk of hypokalemia.

Sodium-glucose Cotranspor...

Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials